Precision BioSearch supports AdvanCell's US expansion
Precision BioSearch is pleased to announce its partnership with AdvanCell, a global leader in radioligand therapy, to appoint Eugene Borelli as VP, Global Head of Quality.
Eugene brings deep expertise in quality systems and compliance from leadership roles at Orano Med and SOFIE, both focused on radiopharmaceuticals. He will play a pivotal role in supporting AdvanCell’s next phase of growth as the company progresses its clinical pipeline and expands its international presence, particularly in the United States, to advance its mission to deliver innovative Pb-212-based targeted alpha therapies that change the course of cancer treatment.
Commenting on the appointment, Andrew Adamovich, Founder and CEO of AdvanCell, said:
AdvanCell is a leader in radioligand therapy—specifically targeted alpha therapy using Lead-212. The quality of candidates that Precision BioSearch introduced to us was excellent. Malcolm and Jemma were highly engaged in understanding our needs and proactive in supporting us throughout the process. We are delighted with the outcome, which strengthens a critical business function as we progress our clinical pipeline and scale our U.S. operations.
